Syncona has added two up-and-coming cancer companies to its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.
The Netherlands-based biotech is focused on lead asset roginolisib, which is described as the first allosteric modulator of PI3Kδ. The candidate has already demonstrated long-term safety and promising efficacy in a phase 1b trial in a rare eye cancer called uveal melanoma (UM), the biotech said in a June 20 release.
“To date, no company has been able to successfully target this well-known cancer pathway with sufficient precision,” Roel Bulthuis, managing partner and head of investments at Syncona as well as a board member of iOnctura, said in the release. “By allosterically modulating PI3Kδ, iOnctura has achieved a new level of precision and could be the first company to develop a clinically meaningful medicine targeting this pathway.”
The other cancer-focused biotech that Syncona has parked in its portfolio is Yellowstone, a U.K.-based company targeting human leukocyte antigen (HLA) class II expression in a range of common cancers.
Syncona has given the preclinical company, which spun out of the University of Oxford, £16.5 million ($20.9 million) in series A funds to build up its pipeline. The biotech is founded on the work of Paresh Vyas, Ph.D., a professor of hematology at the university who built up a biobank of samples from over 3,000 patients with acute myeloid leukemia (AML).
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.